ALKS
Drug Manufacturers - Specialty & Generic · Healthcare
COO, CEO, CFO
2024-02-01–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Alkermes plc. publishes a filing, an earnings call transcript or a press release.
Get ALKS alertsBlair C. Jackson is recorded as CEO at Alkermes plc. (ALKS) since August 1, 2026, CFO at Alkermes plc. (ALKS) since February 1, 2024 and COO at Alkermes plc. (ALKS). The newest filing on record that lists Blair C. Jackson as COO at Alkermes plc. (ALKS) is dated April 6, 2026. Alkermes plc. reported in an 8-K filed February 25, 2026 that Blair C. Jackson was appointed Chief Executive Officer, effective August 1, 2026. Alkermes plc. reported in an 8-K filed February 5, 2024 that Blair C. Jackson was appointed interim principal financial officer, effective February 1, 2024. The proxy statement of Alkermes plc. reports total compensation of $4,030,905 for Blair C. Jackson in fiscal 2025, including a base salary of $736,450. Disclosed compensation is on record for 5 fiscal years. Blair C. Jackson has spoken on 1 earnings call across 1 company, most recently for Alkermes plc. on November 3, 2026. Alkermes plc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Alkermes plc. includes Mr. Richard F. Pops (CEO), Iain M. Brown (CFO and Chief Accounting Officer), Blair Jackson (COO) and 7 others.
“On February 24, 2026, the Board appointed Blair C. Jackson, the Company's current Executive Vice President, Chief Operating Officer, to serve as the Company's Chief Executive Officer, effective August 1, 2026, following Mr. Pops' retirement.”
“On February 1, 2024, the board of directors of Alkermes plc (the “Company”) designated Blair C. Jackson, Executive Vice President, Chief Operating Officer of Alkermes, Inc., a wholly-owned subsidiary of the Company, as the Company’s interim principal financial officer”
“On my first quarterly call as CEO of Alkermes, I'd like to start with a few thoughts on the opportunity ahead and the priorities that will guide us. We have a clear strategy and a strong foundation.”
2026-08-01–present
2024-02-01–present
Start not stated–present
Last confirmed April 6, 2026
ALKS
Drug Manufacturers - Specialty & Generic · Healthcare
COO, CEO, CFO
2024-02-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Alkermes plc. (ALKS) | Executive Vice President, Chief Operating Officer; Former Interim Principal Financial Officer | $736,450 | $4,030,905 |
| 2024 | Alkermes plc. (ALKS) | Executive Vice President, Chief Operating Officer and Chief Risk Officer; Interim Principal Financial Officer | $715,000 | $4,891,034 |
| 2023 | Alkermes plc. (ALKS) | Executive Vice President, Chief Operating Officer and Chief Risk Officer; Interim Principal Financial Officer | $650,000 | $4,561,915 |
| 2022 | Alkermes plc. (ALKS) | Executive Vice President, Chief Operating Officer and Chief Risk Officer; Interim Principal Financial Officer | $600,000 | $4,470,120 |
| 2021 | Alkermes plc. (ALKS) | Executive Vice President, Chief Operating Officer and Chief Risk Officer | $540,000 | $3,769,824 |